Literature DB >> 12686489

Acyl glucuronide reactivity in perspective: biological consequences.

Mark J Bailey1, Ronald G Dickinson.   

Abstract

The metabolic conjugation of exogenous and endogenous carboxylic acid substrates with endogenous glucuronic acid, mediated by the uridine diphosphoglucuronosyl transferase (UGT) superfamily of enzymes, leads to the formation of acyl glucuronide metabolites. Since the late 1970s, acyl glucuronides have been increasingly identified as reactive electrophilic metabolites, capable of undergoing three reactions: intramolecular rearrangement, hydrolysis, and intermolecular reactions with proteins leading to covalent drug-protein adducts. This essential dogma has been accepted for over a decade. The key question proposed by researchers, and now the pharmaceutical industry, is: does or can the covalent modification of endogenous proteins, mediated by reactive acyl glucuronide metabolites, lead to adverse drug reactions, perhaps idiosyncratic in nature? This review evaluates the evidence for acyl glucuronide-derived perturbation of homeostasis, particularly that which might result from the covalent modification of endogenous proteins and other macromolecules. Because of the availability of acyl glucuronides for test tube/in vitro experiments, there is now a substantial literature documenting their rearrangement, hydrolysis and covalent modification of proteins in vitro. It is certain from in vitro experiments that serum albumin, dipeptidyl peptidase IV, tubulin and UGTs are covalently modified by acyl glucuronides. However, these in vitro experiments have been specifically designed to amplify any interference with a biological process in order to find biological effects. The in vivo situation is not at all clear. Certainly it must be concluded that all humans taking carboxylate drugs that form reactive acyl glucuronides will form covalent drug-protein adducts, and it must also be concluded that this in itself is normally benign. However, there is enough in vivo evidence implicating acyl glucuronides, which, when backed up by in vivo circumstantial and documented in vitro evidence, supports the view that reactive acyl glucuronides may initiate toxicity/immune responses. In summary, though acyl glucuronide-derived covalent modification of endogenous macromolecules is well-defined, the work ahead needs to provide detailed links between such modification and its possible biological consequences.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12686489     DOI: 10.1016/s0009-2797(03)00020-6

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  18 in total

Review 1.  Clinical mycophenolic acid monitoring in liver transplant recipients.

Authors:  Hao Chen; Bing Chen
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  The occurrence of diarrhea not related to the pharmacokinetics of MPA and its metabolites in liver transplant patients.

Authors:  Zhang Wei Xia; Chen Yong Jun; Chen Hao; Chen Bing; Shi Min Min; Xie Jun Jie
Journal:  Eur J Clin Pharmacol       Date:  2010-05-15       Impact factor: 2.953

Review 3.  Role of biotransformation studies in minimizing metabolism-related liabilities in drug discovery.

Authors:  Yue-Zhong Shu; Benjamin M Johnson; Tian J Yang
Journal:  AAPS J       Date:  2008-03-13       Impact factor: 4.009

4.  Expression of drug metabolizing enzymes and transporters in the cochlea: Implications for drug delivery and ototoxicity.

Authors:  Stefanie Kennon-McGill; Melissa M Clemens; Mitchell R McGill
Journal:  Hear Res       Date:  2019-05-15       Impact factor: 3.208

5.  Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs).

Authors:  Jin Zhou; Upendra A Argikar; John O Miners
Journal:  Methods Mol Biol       Date:  2021

6.  CPY3A4-mediated α-hydroxyaldehyde formation in saquinavir metabolism.

Authors:  Feng Li; Jie Lu; Xiaochao Ma
Journal:  Drug Metab Dispos       Date:  2013-11-08       Impact factor: 3.922

Review 7.  Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat.

Authors:  Bishoy Kamel; Garry G Graham; Kenneth M Williams; Kevin D Pile; Richard O Day
Journal:  Clin Pharmacokinet       Date:  2017-05       Impact factor: 6.447

8.  Glucuronidation and covalent protein binding of benoxaprofen and flunoxaprofen in sandwich-cultured rat and human hepatocytes.

Authors:  Jennifer Q Dong; Philip C Smith
Journal:  Drug Metab Dispos       Date:  2009-09-22       Impact factor: 3.922

9.  Quantitation of celecoxib and four of its metabolites in rat blood by UPLC-MS/MS clarifies their blood distribution patterns and provides more accurate pharmacokinetics profiles.

Authors:  Yong Ma; Song Gao; Ming Hu
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2015-07-19       Impact factor: 3.205

Review 10.  Filling and mining the reactive metabolite target protein database.

Authors:  Robert P Hanzlik; Jianwen Fang; Yakov M Koen
Journal:  Chem Biol Interact       Date:  2008-09-06       Impact factor: 5.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.